CORE--PHARMACOLOGY CORE

药理学核心实验室的目标是a）执行 方案要求测量获得的临床样本中的药物水平 来自UTMB的患者或来自其他ACTU研究中心的患者。 B）开发， 改进或评估新的方法， 抗艾滋病药物及相关病毒的药理学检测方法 剂. 由于高压液相色谱法的可用性 气相色谱/质谱法、核磁共振 光谱法、紫外（二极管阵列）和荧光分光光度法 和RIA，药代动力学实验室能够进行 使用最新药理学技术监测治疗药物 技术. 根据我们以前收集和保存标本的经验 库存和获取我们医院和其他医院的患者样本 机构，我们能够接收，存储和分析临床 在我们的医院或其他ACTU研究中心采集的样本。 因为我们有 三个HPLC，并进行了RIA的其他代理商，我们认为， 药代动力学实验室将能够分析约500 - 1000 药物水平/年的实验药物，如核苷类似物。 我们已经开发和利用了几种新的技术进行定量 临床样本中的相关药物。 我们利用分析 信息和血液中的药物水平，以获得药代动力学数据， 用于治疗HIV感染和其他疾病的药物。

The objectives of the Pharmacology Core laboratory are a) to perform protocol mandated measurements of drug levels in clinical samples obtained from patients at UTMB or received from other ACTU sites. b) to develop, improve or evaluate new methodologies that will be implemented as pharmacologic detection procedures of antiAIDS drugs and related viral agents. Because of the availability of high pressure liquid chromatography Gas Chromatography/Mass Spectrometry, Nuclear Magnetic Resonance Spectrometry, ultraviolet (diod array) and Fluorescent spectrophotometry and RIA, the pharmacokinetic laboratory is capable of conducting therapeutic drug monitoring using state of the art pharmacological techniques. Based upon our previous experience in collecting and maintaining a specimen inventory and acquiring patient samples in our hospitals and from other institutions, we are capable of receiving, storing and analyzing clinical samples collected in our hospitals or in other ACTU sites. Because we have three HPLCs and have performed RIAs for other agents, we feel that the pharmacokinetics laboratory will be capable of analyzing about 500-1000 drug levels/year for an experimental drug agent such as nucleoside analogs. We have developed and utilized several new techniques for the quantitation of relevant drugs in clinical samples. We utilized the analytical information and the drug levels in blood to obtain pharmacokinetic data for agents utilized in treatment of HIV infection and other diseases.